Matches in Nanopublications for { ?s ?p "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP499169.RAAp5objdMNdzaGHBh4_vj2Ab8DybP7AsdmlKL2cWJNtM130_assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499169.RAAp5objdMNdzaGHBh4_vj2Ab8DybP7AsdmlKL2cWJNtM130_provenance.
- NP499166.RAXXWpWLahLn53tjOwZ5c5RuhhtqZFnQADmptaNMbvxIc130_assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499166.RAXXWpWLahLn53tjOwZ5c5RuhhtqZFnQADmptaNMbvxIc130_provenance.
- NP499168.RAUrHEA-QOA76xaeK-zd2bGA5rttJpPnbmHU3lWK1rEJ4130_assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499168.RAUrHEA-QOA76xaeK-zd2bGA5rttJpPnbmHU3lWK1rEJ4130_provenance.
- NP499167.RAm-E6_K1Cq9tKX37nAburHQkKVNP_4tiNtf2gE6_fYqk130_assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499167.RAm-E6_K1Cq9tKX37nAburHQkKVNP_4tiNtf2gE6_fYqk130_provenance.
- NP499163.RAK94Ey1cqpEK18k07XAwovm2CzmWNf0ZRe-EVJ2DlxTU130_assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499163.RAK94Ey1cqpEK18k07XAwovm2CzmWNf0ZRe-EVJ2DlxTU130_provenance.
- NP499162.RA8kA90AKJ-lM5NyxcJmvQ7FI0T6sN61lr-u3884bdgAQ130_assertion description "[PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499162.RA8kA90AKJ-lM5NyxcJmvQ7FI0T6sN61lr-u3884bdgAQ130_provenance.